Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Not listed Phase 3 Interventional

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

ClinicalTrials.gov ID: NCT02901717

Public ClinicalTrials.gov record NCT02901717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination With Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution as an adjuctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI). Approximately 144 subjects who have been diagnosed with CRBSI/CLABSI and who meet all necessary criteria for the study will be randomized in a 1:1 ratio to 1 of 2 treatment arms: * MLT Arm: Mino-Lok therapy; or * Control Arm: Antibiotic lock (±heparin). The antibiotic lock (ALT) should be comprised of the best available therapy at the sites based on standard institutional practices or recommendations from the Infectious Diseases Society of America (IDSA) guidelines.

Study identification

NCT ID
NCT02901717
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Enrollment
144 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2018
Primary completion
Nov 30, 2022
Completion
Feb 28, 2023
Last update posted
Apr 18, 2022

2018 – 2023

United States locations

U.S. sites
19
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
Georgetown University Hospital Washington D.C. District of Columbia 20007 Recruiting
University of Florida Shands Hospital Gainesville Florida 32608 Recruiting
Edward Hines Jr. VA Hospital Hines Illinois 60141 Recruiting
AMG Oncology Park Ridge Illinois 60068 Recruiting
Indiana Blood and Marrow Institute Indianapolis Indiana 46237 Recruiting
Ascension Via Christi Hospital Wichita Kansas 67214 Recruiting
University of Kentucky Medical Center Lexington Kentucky 40536 Suspended
Anne Arundel Medical Center Annapolis Maryland 21401 Suspended
Massachusetts General Hospital Boston Massachusetts 02114 Recruiting
Henry Ford Health Systems Detroit Michigan 48202 Recruiting
William Beaumont Hospital Troy Michigan 48083 Suspended
VA Sierra Nevada Health Care Systems Reno Nevada 89502 Recruiting
Saint Michael's Medical Center Newark New Jersey 07102 Recruiting
Carolinas Medical Center Charlotte North Carolina 28203 Recruiting
East Carolina University Greenville North Carolina 27858 Recruiting
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 Recruiting
University of Texas MD Anderson Cancer Center Houston Texas 77030 Recruiting
Salem VA Medical Center Salem Virginia 24153 Recruiting
Seattle Children's Hospital Seattle Washington 98105 Suspended

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02901717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 18, 2022 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02901717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →